The closing price of Vaxart Inc (NASDAQ: VXRT) was $1.23 for the day, down -2.00% from the previous closing price of $1.25. In other words, the price has decreased by -$0.0250 from its previous closing price. On the day, 1203845 shares were traded.
Ratios:
Our analysis of VXRT’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 5.07 and its Current Ratio is at 5.07. In the meantime, Its Debt-to-Equity ratio is 0.37 whereas as Long-Term Debt/Eq ratio is at 0.32.
On November 02, 2021, Cantor Fitzgerald started tracking the stock assigning a Overweight rating and target price of $15.
B. Riley Securities Downgraded its Buy to Neutral on June 29, 2021, whereas the target price for the stock was revised from $13 to $9.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, VXRT now has a Market Capitalization of 190.99M and an Enterprise Value of 159.21M. For the stock, the TTM Price-to-Sale (P/S) ratio is 49.72 while its Price-to-Book (P/B) ratio in mrq is 2.60. Its current Enterprise Value per Revenue stands at 205.16 whereas that against EBITDA is -1.99.
Stock Price History:
Over the past 52 weeks, VXRT has reached a high of $1.59, while it has fallen to a 52-week low of $0.53. The 50-Day Moving Average of the stock is 0.9198, while the 200-Day Moving Average is calculated to be 0.8328.
Shares Statistics:
VXRT traded an average of 1.80M shares per day over the past three months and 2.23M shares per day over the past ten days. A total of 168.84M shares are outstanding, with a floating share count of 167.70M. Insiders hold about 0.67% of the company’s shares, while institutions hold 18.57% stake in the company. Shares short for VXRT as of Feb 15, 2024 were 12.67M with a Short Ratio of 7.05, compared to 11.48M on Jan 12, 2024. Therefore, it implies a Short% of Shares Outstanding of 8.26% and a Short% of Float of 8.31%.
Earnings Estimates
The firm’s stock currently is rated by 2 analysts. On average, analysts expect EPS of -$0.14 for the current quarter, with a high estimate of -$0.13 and a low estimate of -$0.16, while EPS last year was -$0.18. The consensus estimate for the next quarter is $0, with high estimates of $0 and low estimates of $0.
Analysts are recommending an EPS of between -$0.56 and -$0.66 for the fiscal current year, implying an average EPS of -$0.61. EPS for the following year is -$0.49, with 2 analysts recommending between -$0.4 and -$0.58.
Revenue Estimates
It is expected that $90B in revenue will be generated in the current quarter, according to 2 analysts. It ranges from a high estimate of $2.4M to a low estimate of $100k. As of the current estimate, Vaxart Inc’s year-ago sales were $22k, an estimated increase of 5,581.80% from the year-ago figure. For the next quarter, 1 analysts are estimating revenue of $2.4M, an increase of 200.00% less than the figure of $5,581.80% in the same quarter last year. There is a high estimate of $2.4M for the next quarter, whereas the lowest estimate is $2.4M.
A total of 2 analysts have provided revenue estimates for VXRT’s current fiscal year. The highest revenue estimate was $4.2M, while the lowest revenue estimate was $2M, resulting in an average revenue estimate of $3.1M. In the same quarter a year ago, actual revenue was $107k, up 2,797.20% from the average estimate.
